JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 54(2020) N 5 p. 623-632; DOI 10.1134/S0026893320050039 Full Text

D.V. Glazkova1,2, F.A. Urusov1,2*, E.V. Bogoslovskaya1, G.A. Shipulin1

Retrovirus Restriction Factor TRIM5α: The Mechanism of Action and Prospects for Use in Gene Therapy of HIV Infection

1Center for Strategic Planning and Management of Medical and Biological Health Risks, Federal Medical-Biological Agency of the Russian Federation, Moscow, 119992 Russia
2Izmerov Research Institute of Occupational Health, Moscow, 105275 Russia

*flanger.fx@mail.ru
Received - 2020-03-19; Revised - 2020-04-14; Accepted - 2020-04-16

It is commonly known that the antiviral activity of the TRIM5α protein, the intracellular retrovirus restriction factor, underlies the resistance of the Old World monkeys to HIV-1. This fact suggests that TRIM5α can potentially be used to cure HIV-1 infection in humans. The present review considers the mechanisms of HIV-1 replication inhibition by the TRIM5a protein and the prospects for using it in gene therapy of HIV infection.

TRIM5α, HIV-1, gene therapy



JMB-FOOTER RAS-JOURNALS